Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
J Clin Lipidol ; 2023 Nov 27.
Article in English | MEDLINE | ID: mdl-38065715

ABSTRACT

Elevated lipoprotein(a) [Lp(a)] is independently associated with cardiovascular disease (CVD). In a recent long-term follow-up study involving children with familial hypercholesterolemia, Lp(a) levels contributed significantly to early atherosclerosis, as measured by carotid intima-media thickness (cIMT). To determine if this holds true for children without FH, we conducted a 20-year follow-up study, examining 88 unaffected siblings (mean age: 12.9 years) of children with FH. No significant association was found between Lp(a) and cIMT during follow-up (ß-adjusted [95% CI] = 0.0001 [-0.008 to 0.008] mm per 50 nmol/L increase Lp(a), p = 0.97). In conclusion, our findings suggest that elevated levels of Lp(a) do not play a significant role in arterial wall thickening among children without FH during the 20-year follow-up period. This leads us to consider the possibility that cIMT may not be a suitable marker for detecting potential subtle changes in the arterial wall mediated by Lp(a) in the young, general population. However, it could also be that elevated Lp(a) is only a significant risk factor for atherosclerosis in the presence of other risk factors such as FH.

2.
J Intern Med ; 287(1): 2-18, 2020 01.
Article in English | MEDLINE | ID: mdl-31858669

ABSTRACT

There is compelling evidence that the elevated plasma lipoprotein(a) [Lp(a)] levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) in the general population. Like low-density lipoprotein (LDL) particles, Lp(a) particles contain cholesterol and promote atherosclerosis. In addition, Lp(a) particles contain strongly proinflammatory oxidized phospholipids and a unique apoprotein, apo(a), which promotes the growth of an arterial thrombus. At least one in 250 individuals worldwide suffer from the heterozygous form of familial hypercholesterolemia (HeFH), a condition in which LDL-cholesterol (LDL-C) is significantly elevated since birth. FH-causing mutations in the LDL receptor gene demonstrate a clear gene-dosage effect on Lp(a) plasma concentrations and elevated Lp(a) levels are present in 30-50% of patients with HeFH. The cumulative burden of two genetically determined pro-atherogenic lipoproteins, LDL and Lp(a), is a potent driver of ASCVD in HeFH patients. Statins are the cornerstone of treatment of HeFH, but they do not lower the plasma concentrations of Lp(a). Emerging therapies effectively lower Lp(a) by as much as 90% using RNA-based approaches that target the transcriptional product of the LPA gene. We are now approaching the dawn of an era, in which permanent and significant lowering of the high cholesterol burden of HeFH patients can be achieved. If outcome trials of novel Lp(a)-lowering therapies prove to be safe and cost-effective, they will provide additional risk reduction needed to effectively treat HeFH and potentially lower the CVD risk in these high-risk patients even more than currently achieved with LDL-C lowering alone.


Subject(s)
Coronary Artery Disease/prevention & control , Hyperlipoproteinemia Type II/therapy , Lipoprotein(a)/blood , Aortic Valve , Blood Component Removal , Cholesterol, LDL/blood , Coronary Artery Disease/etiology , Heart Valve Diseases/etiology , Heart Valve Diseases/prevention & control , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hyperlipoproteinemia Type II/blood , Hypolipidemic Agents/therapeutic use , Oligonucleotides, Antisense/therapeutic use , PCSK9 Inhibitors , Practice Guidelines as Topic , Receptors, LDL/genetics , Risk Factors , Vascular Calcification/etiology , Vascular Calcification/prevention & control
3.
J Intern Med ; 280(5): 509-517, 2016 11.
Article in English | MEDLINE | ID: mdl-27237700

ABSTRACT

BACKGROUND: Studies have shown that lipoprotein(a) [Lp(a)], an important carrier of oxidized phospholipids, is causally related to calcific aortic valve stenosis (CAVS). Recently, we found that Lp(a) mediates the development of CAVS through autotaxin (ATX). OBJECTIVE: To determine the predictive value of circulating ATX mass and activity for CAVS. METHODS: We performed a case-control study in 300 patients with coronary artery disease (CAD). Patients with CAVS plus CAD (cases, n = 150) were age- and gender-matched (1 : 1) to patients with CAD without aortic valve disease (controls, n = 150). ATX mass and enzymatic activity and levels of Lp(a) and oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) were determined in fasting plasma samples. RESULTS: Compared to patients with CAD alone, ATX mass (P < 0.0001), ATX activity (P = 0.05), Lp(a) (P = 0.003) and OxPL-apoB (P < 0.0001) levels were elevated in those with CAVS. After adjustment, we found that ATX mass (OR 1.06, 95% CI 1.03-1.10 per 10 ng mL-1 , P = 0.001) and ATX activity (OR 1.57, 95% CI 1.14-2.17 per 10 RFU min-1 , P = 0.005) were independently associated with CAVS. ATX activity interacted with Lp(a) (P = 0.004) and OxPL-apoB (P = 0.001) on CAVS risk. After adjustment, compared to patients with low ATX activity (dichotomized at the median value) and low Lp(a) (<50 mg dL-1 ) or OxPL-apoB (<2.02 nmol L-1 , median) levels (referent), patients with both higher ATX activity (≥84 RFU min-1 ) and Lp(a) (≥50 mg dL-1 ) (OR 3.46, 95% CI 1.40-8.58, P = 0.007) or OxPL-apoB (≥2.02 nmol L-1 , median) (OR 5.48, 95% CI 2.45-12.27, P < 0.0001) had an elevated risk of CAVS. CONCLUSION: Autotaxin is a novel and independent predictor of CAVS in patients with CAD.


Subject(s)
Aortic Valve Stenosis/blood , Aortic Valve Stenosis/etiology , Coronary Artery Disease/blood , Coronary Artery Disease/complications , Lipoprotein(a)/blood , Phospholipids/blood , Phosphoric Diester Hydrolases/blood , Aged , Apolipoprotein B-100/blood , Case-Control Studies , Female , Humans , Male , Oxidation-Reduction , Risk Factors
4.
Minerva Cardioangiol ; 55(6): 821-37, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18091649

ABSTRACT

The pathogenesis of atherosclerosis is mediated by genetic susceptibility along with a variety of cardiovascular risk factors and environment influences. As atherosclerotic lesions progress, they manifest several features typical of chronic inflammation, such as the presence of monocyte/macrophages, T-cells and inflammatory cytokines. This inflammatory response is fueled and enhanced by oxidative stress, which may be the link between lipid disorders and inflammation. Oxidation of lipoproteins is intimately involved in all stages of atherosclerosis and oxidative byproducts co-localize with inflammatory cells. When low density lipoprotein enters the subintimal space, it is oxidized by several mechanisms, including both enzymatic and non-enzymatic pathways and becomes a ligand for scavenger receptors on macrophages leading to generation of foam cells. Oxidized LDL is not only pro-inflammatory and pro-atherogenic, but several of the neoepitopes generated during oxidation are highly immunogenic and result in the generation of autoantibodies. Autoantibodies to OxLDL are found within atherosclerotic lesions and in apparently healthy subjects, as well as patients with various manifestations of cardiovascular disease. In this article, the role of circulating autoantibodies to OxLDL in cardiovascular disease will be reviewed. Although controversy still exists, the overall evidence supports the notion that IgG autoantibodies to OxLDL are associated with pro-atherogenic properties and IgM autoantibodies to OxLDL with atheroprotective properties. Whether such antibodies have a modulating role or are merely reflectors of atherogenesis has not been fully determined. Data is also emerging on the role of natural antibodies, which are primarily of the IgM class, that recognize oxidation-specific epitopes. Among other properties, these antibodies may be involved in housekeeping functions in binding and clearing pro-inflammatory oxidized lipids and therefore may be atheroprotective. Several studies have also recently evaluated the potential therapeutic role of antibodies to OxLDL either through active immunization using OxLDL or model oxidation-specific epitopes as immunogens or through passive immunization with human antibodies directed to oxidation-specific epitopes. Although these investigation are at an early stage, they show promise that immune modulation may lead to novel approaches to treat atherosclerosis and cardiovascular disease.


Subject(s)
Antibodies/immunology , Autoantibodies/immunology , Cardiovascular Diseases/immunology , Cardiovascular Diseases/therapy , Lipoproteins, LDL/immunology , Adult , Aged , Animals , Antibody Formation , Atherosclerosis/immunology , Atherosclerosis/therapy , Disease Models, Animal , Disease Progression , Epitopes , Female , Humans , Hypolipidemic Agents/therapeutic use , Male , Mice , Middle Aged , Odds Ratio , Oxidation-Reduction , Oxidative Stress , Rabbits , Risk Factors , Vaccination
5.
J Thromb Thrombolysis ; 11(3): 217-21, 2001 May.
Article in English | MEDLINE | ID: mdl-11577260

ABSTRACT

Point-of-care whole blood coagulation tests are critical in the management of patients who undergo percutaneous coronary intervention. The Hemochron and HemoTec devices have been traditionally used to measure the activated clotting time (ACT) in the cardiac catheterization laboratory. The heparin management test (HMT) was recently introduced into clinical practice as an alternative method to current ACT measurements that uses a different sample volume, contact activators and detection system to measure whole blood coagulation. We compared the HMT to the HemoTec ACT in 68 prospectively enrolled patients (127 blood samples) undergoing percutaneous coronary intervention. Measurements were performed 10 minutes after the initial heparin bolus and thereafter at the discretion of the attending physician. The mean HMT was 41 seconds higher (approximately 15%) than the HemoTec ACT (HMT 304+/-59 vs. ACT 263+/-52, P< 0.0001), but there was a significant correlation between the methods (r=0.77, P<0.0001). However, there was increasing disagreement between the two methods as the level of anticoagulation increased. The relationship between HMT and ACT was similar in patients in whom glycoprotein IIb/IIIa inhibitors were used. The HMT, therefore, appears to be more sensitive to heparin anticoagulation that the HemoTec ACT and correlates well with it in the range required for percutaneous coronary intervention.


Subject(s)
Angioplasty, Balloon, Coronary , Blood Coagulation Tests/instrumentation , Drug Monitoring/instrumentation , Heparin/administration & dosage , Blood Coagulation Tests/methods , Blood Coagulation Tests/standards , Cohort Studies , Heparin/pharmacology , Humans , Platelet Glycoprotein GPIIb-IIIa Complex/administration & dosage , Platelet Glycoprotein GPIIb-IIIa Complex/pharmacology , Point-of-Care Systems , Prospective Studies , Whole Blood Coagulation Time
6.
Arterioscler Thromb Vasc Biol ; 21(8): 1333-9, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11498462

ABSTRACT

Autoantibodies to oxidation-specific epitopes of low density lipoprotein (LDL), such as malondialdehyde-modified LDL (MDA-LDL), occur in plasma and atherosclerotic lesions of humans and animals. Plasma titers of such antibodies are correlated with atherosclerosis in murine models, and several such autoantibodies have been cloned. However, human-derived monoclonal antibodies to epitopes of oxidized LDL (OxLDL) have not yet been reported. We constructed a phage display antibody library from a patient with high plasma anti-MDA-LDL titers and isolated 3 monoclonal IgG Fab antibodies, which specifically bound to MDA-LDL. One of these, IK17, also bound to intact OxLDL as well as to its lipid and protein moieties but not to those of native LDL. IK17 inhibited the uptake of OxLDL by macrophages and also bound to apoptotic cells and inhibited their phagocytosis by macrophages. IK17 strongly immunostained necrotic cores of human and rabbit atherosclerotic lesions. When (125)I-IK17 was injected intravenously into LDL receptor-deficient mice, its specific uptake was greatly enriched in atherosclerotic plaques versus normal aortic tissue. Human autoantibodies to OxLDL have important biological properties that could influence the natural course of atherogenesis.


Subject(s)
Antibodies, Monoclonal , Arteriosclerosis/etiology , Autoantibodies/metabolism , Immunoglobulin Fab Fragments , Lipoproteins, LDL/immunology , Lipoproteins, LDL/metabolism , Macrophages/metabolism , Animals , Arteriosclerosis/immunology , Arteriosclerosis/metabolism , Epitopes , Humans , Malondialdehyde
7.
Catheter Cardiovasc Interv ; 53(3): 289-95, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11458402

ABSTRACT

We assessed the angiographic size of the common femoral artery (CFA) and the influence of demographics and comorbidites. In addition, the location of the CFA bifurcation and the site of femoral puncture were also assessed. Consecutive CFA angiograms (n = 200) were prospectively analyzed. CFA diameter was 6.9 +/- 1.4 mm and length 43.3 +/- 16.2 mm. By multivariate analysis, only diabetes (P < 0.001), female gender (P < 0.0005), and small body surface area (P < 0.01) predicted small vessel size. Vessel length correlated with patient height (P < 0.0005). CFA bifurcation occurred at or below the femoral head center in 98.5%. The femoral puncture was into a vessel other than the CFA in 13%, and 54% of punctures were in a less than ideal anatomical location. In conclusion, the CFA is a relatively small diameter vessel, particularly in diabetics and women. Puncture above the femoral head center and below the superior margin of the acetabulum accurately predicts an ideal puncture site. Thus, routine fluoroscopic guidance should be considered. Cathet Cardiovasc Intervent 2001;53:289-295.


Subject(s)
Cardiac Catheterization , Catheterization, Peripheral , Coronary Disease/diagnostic imaging , Femoral Artery/diagnostic imaging , Peripheral Vascular Diseases/diagnostic imaging , Aged , Comorbidity , Constriction, Pathologic/diagnostic imaging , Constriction, Pathologic/etiology , Coronary Angiography , Coronary Disease/complications , Demography , Female , Humans , Male , Middle Aged , Peripheral Vascular Diseases/etiology , Prospective Studies , Risk Factors
9.
Arterioscler Thromb Vasc Biol ; 21(1): 95-100, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11145939

ABSTRACT

Autoantibodies to oxidized low density lipoprotein (OxLDL) are elevated in some human populations with increased risk of atherosclerosis. To determine whether autoantibody levels to epitopes of OxLDL reflect the extent of aortic atherosclerosis and the content of OxLDL, we measured IgG and IgM autoantibody titers to malondialdehyde (MDA)-LDL and copper-oxidized LDL (Cu-OxLDL) in 43 LDL receptor-deficient mice consuming atherogenic and regression diets. Antibody titers were correlated to percent atherosclerotic surface area, aortic weight, and aortic OxLDL content, measured as the in vivo uptake of (125)I-MDA2, a monoclonal antibody to MDA-LDL. All mice were fed an atherogenic diet for 6 months, and 1 group was euthanized. The other 3 groups were fed an atherogenic diet (fat/CHOL group), normal mouse chow (chow group), or mouse chow supplemented with vitamins E and C (chow+VIT group) for an additional 6 months. After dietary intervention, compared with their own baseline, autoantibody titers to MDA-LDL and Cu-OxLDL increased significantly in the fat/CHOL group, whereas they did not change or decreased significantly in the chow and chow+VIT groups. Aortic weight and surface area showed significant progression in the fat/CHOL group, mild progression in the chow group, and no progression in the chow+VIT group (P<0.001), whereas OxLDL content actually decreased in the latter 2 groups (P<0.001). Significant correlations were seen with MDA-LDL autoantibody titers and OxLDL content (IgM, R=0.64 and P=0.0009; IgG, R=0.52 and P=0.009), as well as with percent surface area and aortic weight. These data support the hypothesis that autoantibody titers to OxLDL reflect changes in OxLDL content in atherosclerotic lesions of LDL receptor-deficient mice. Whether autoantibody titers to OxLDL will provide similar valuable insights into the extent of human atherosclerosis, particularly anatomic measurements of plaque burden and OxLDL content, remains to be determined.


Subject(s)
Aorta/metabolism , Arteriosclerosis/immunology , Arteriosclerosis/metabolism , Autoantibodies/blood , Lipoproteins, LDL/immunology , Lipoproteins, LDL/metabolism , Receptors, LDL/deficiency , Receptors, LDL/genetics , Animals , Aorta/pathology , Arteriosclerosis/genetics , Arteriosclerosis/pathology , Disease Models, Animal , Male , Mice , Mice, Knockout , Oxidation-Reduction
10.
Arterioscler Thromb Vasc Biol ; 20(3): 689-97, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10712392

ABSTRACT

To determine whether labeled antibodies against oxidized LDL (OxLDL) offer advantages for quantifying atherosclerosis, we compared in vivo aortic uptake of (125)I-labeled MDA2, a monoclonal antibody against malondialdehyde-lysine epitopes), atherosclerotic surface area, and aortic weight in Watanabe heritable hyperlipidemic and New Zealand White rabbits and in low density lipoprotein receptor-deficient (LDLR(-/-)) and apolipoprotein E-deficient (apoE(-/-)) mice. Absolute and specific uptakes of (125)I-MDA2 were significantly greater in plaque than in normal aortas. Uptake of (125)I-MDA2 significantly correlated with aortic weight and percent atherosclerotic surface area in rabbits and mice. To assess whether (125)I-MDA2 uptake reflects changes in lesion content of OxLDL, in a separate study, extensive atherosclerosis was induced in 4 groups of LDLR(-/-) mice by feeding them a high fat/cholesterol diet for 6 months. A baseline group was euthanized at this time. The remaining groups were fed "regression" diets (chow or chow+1% vitamin E+0.05% vitamin C) or the high fat/cholesterol diet for 6 more months. When atherosclerosis was measured as percent surface area or aortic weight, there was strong progression in the high fat/cholesterol group, moderate progression in the chow group, and no progression in the chow+vitamin E+vitamin C group compared with the baseline group. The (125)I-MDA2 method also yielded a significant increase in atherosclerosis in the high fat/cholesterol group but significant decreases in the chow and chow+vitamin E+vitamin C groups. Immunocytochemistry showed fewer oxidation-specific epitopes in lesions from the chow and chow+vitamin E+vitamin C groups. Thus, the uptake of (125)I-MDA2 correlates well with traditional measures of atherosclerosis but also reflects reduced plaque OxLDL content after hypocholesterolemic intervention.


Subject(s)
Antibodies, Monoclonal/pharmacokinetics , Arteriosclerosis/metabolism , Lipoproteins, LDL/analysis , Malondialdehyde/immunology , Receptors, LDL/genetics , Animals , Antibody Specificity , Aorta, Thoracic/metabolism , Aorta, Thoracic/pathology , Arteriosclerosis/diagnosis , Arteriosclerosis/pathology , Cholesterol/blood , Diet, Atherogenic , Epitopes/metabolism , Hyperlipidemias/diagnosis , Hyperlipidemias/metabolism , Hyperlipidemias/pathology , Iodine Radioisotopes/pharmacokinetics , Mice , Mice, Knockout , Organ Size , Oxidation-Reduction , Rabbits , Staining and Labeling , Triglycerides/blood , Vitamin E/blood
11.
J Nucl Cardiol ; 6(1 Pt 1): 41-53, 1999.
Article in English | MEDLINE | ID: mdl-10070840

ABSTRACT

BACKGROUND: Oxidatively modified low-density lipoprotein (LDL) is present in atherosclerotic but not normal arteries and plays a crucial role in the pathogenesis and adverse consequences of atherosclerotic lesions. We previously generated a series of monoclonal antibodies (MoAb) against oxidation-specific neo-epitopes formed during the oxidative modification of LDL. MDA2, a prototype MoAb, recognizes malondialdehyde-lysine epitopes (eg, in malondi-aldehyde-modified LDL) within atherosclerotic lesions. We describe the in vivo characteristics of MDA2 and initial noninvasive imaging studies of atherosclerosis in rabbits. METHODS: To assess the in vivo specificity of MDA2 for atherosclerotic lesions, iodine 125-MDA2 was intravenously injected into 7 LDL-receptor deficient Watanabe heritable hyperlipidemic (WHHL) and 2 normal New Zealand white (NZW) rabbits, and the aortic plaque uptake was evaluated 24 hours later. 125I-Halb, an isotype-matched irrelevant MoAb that binds to human albumin, was injected into 5 WHHL and 2 NZW rabbits as a control. Aortic autoradiography was performed, and the mean uptake of MoAbs was measured as the percent injected dose per gram aortic tissue. Gamma camera imaging was then carried out in 7 WHHL rabbits and 2 NZW rabbits with 99mTc-MDA2. Imaging was carried out at 10 minutes and at 12 or 24 hours. Malondialdehyde-LDL was then injected to clear the blood pool signal, and final images were obtained 2 hours later. RESULTS: Mean uptake of 125I-MDA2 in the entire aorta was 17.4-fold higher in WHHL than in NZW aortas (P < .001), and 2.8-fold higher than 125I-Halb in WHHL aortas. 125I-MDA2 also had higher specificity for lesioned areas than 125I-Halb (plaque/normal ratio 6.3 vs 2.9, P < .001). Autoradiograph of aortas of 125I-MDA2-injected WHHL rabbits revealed uptake in lipid-stained lesions with absence of signal in adjacent normal arterial tissue. Immunostaining of WHHL lesions, which accumulated MDA2 as noted on autoradiography, revealed that uptake was highest in areas with abundant foam cells and in lipid-rich necrotic core areas. Autoradiograph of aortas from NZW rabbits injected with 125I-MDA2 did not yield any visible signal. Planar gamma camera in vivo scintigraphy revealed a visible signal in 4/7 WHHL rabbits, which was confirmed by aortic Sudan staining. CONCLUSION: Radiolabeled MDA2 shows excellent in vivo uptake and specificity for atherosclerotic lesions containing abundant oxidation-specific epitopes. The in vivo imaging studies suggest that noninvasive imaging of oxidation-rich atherosclerotic lesions with radiolabeled MDA2 may be feasible in human beings with optimization of the imaging methods.


Subject(s)
Antibodies, Monoclonal , Arteriosclerosis/diagnostic imaging , Lipoproteins, LDL/immunology , Radioimmunodetection , Animals , Antibodies, Monoclonal/immunology , Antibody Specificity , Aorta/diagnostic imaging , Aorta/immunology , Autoradiography , Epitopes/immunology , Gamma Cameras , Immunohistochemistry , Malondialdehyde/immunology , Oxidation-Reduction , Rabbits
12.
Arterioscler Thromb Vasc Biol ; 19(1): 122-30, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9888874

ABSTRACT

The mechanisms underlying the cardiovascular benefits of Mediterranean-style diets are not fully understood. The high content of monounsaturated fatty acids in Mediterranean-style diets derived from oleate-rich olive oil may be beneficial in reducing low density lipoprotein (LDL) oxidation and its subsequent development of atherogenic properties. This study sought to assess the proinflammatory potential of LDL isolated from subjects consuming a diet naturally rich in olive oil. LDL was isolated from 18 Greek, 18 American, and 11 Greek-Americans subjects, all of whom were living in the United States. Fatty acid composition and vitamin E levels of LDL were determined, as was the extent of copper-mediated LDL oxidation. LDL was also mildly oxidized by exposure to fibroblasts overexpressing 15-lipoxygenase and tested in vitro for bioactivity by determining its ability to stimulate monocyte chemotaxis and adhesion to endothelial cells. To confirm that dietary fatty acids influence the proinflammatory properties of mildly oxidized LDL, LDL was also isolated from 13 healthy American subjects after consumption of an 8-week liquid diet supplemented with either oleic (n=6) or linoleic (n=7) acid and tested for bioactivity in a similar fashion. There were no differences in the baseline lipid profiles among the Greeks, Americans, or Greek-Americans. Oleic acid content in LDL was 20% higher in the Greek compared with the American or Greek-American subjects (P<0.001). The extent of in vitro LDL oxidation, measured by conjugated diene formation, was lower in the Greek subjects (P<0.02), but there was no difference in the lag time. Induction of monocyte chemotaxis and adhesion by mildly oxidized LDL was decreased by 42% in the Greek group compared with the American subjects (P<0.001). There was an inverse correlation between the oleic acid content of LDL and stimulation of monocyte chemotaxis (r=-0.64, P<0.001) and a positive correlation between the polyunsaturated fatty acid content of LDL (total linoleate and arachidonic acids levels in LDL) and stimulation of monocyte chemotaxis (r=0.51, P<0.01) in the entire cohort. There were no differences in LDL vitamin E content between the groups. In the liquid-diet groups, the oleic acid-supplemented group had a 113% higher oleic acid content in LDL and a 46% lower linoleic acid content in LDL than the linoleate-supplemented group (P<0.001), whereas the vitamin E content in LDL was equal in both groups. When exposed to oxidative stress, the LDL enriched in oleic acid promoted less monocyte chemotaxis (52% lower) and reduced monocyte adhesion by 77% in comparison with linoleate-enriched LDL (P<0.001). There was a strong, negative correlation between oleic acid LDL content and monocyte adhesion (r=-0.73, P<0.001) and a strong, positive correlation between polyunsaturated fatty acid LDL content and monocyte adhesion (r=0.87, P<0.001). This study demonstrates that dietary enrichment of LDL with oleic acid is realistic and readily achieved by using diets currently in use in Mediterranean countries. In addition, these data suggest that LDL enriched with oleic acid and reduced in polyunsaturated fatty acids may be less easily converted to a proinflammatory, minimally modified LDL.


Subject(s)
Cell Adhesion/drug effects , Chemotaxis, Leukocyte/drug effects , Lipoproteins, LDL/blood , Monocytes/drug effects , Oleic Acids/administration & dosage , Oxidative Stress , Dietary Fats, Unsaturated/administration & dosage , Fatty Acids/analysis , Fatty Acids/blood , Greece/ethnology , Humans , Linoleic Acid/administration & dosage , Linoleic Acid/blood , Lipoproteins, LDL/pharmacology , Monocytes/physiology , Oleic Acid/blood , Olive Oil , Oxidation-Reduction , Plant Oils/analysis , United States , Vitamin E/blood
13.
J Invasive Cardiol ; 11(5): 316-21, 1999 May.
Article in English | MEDLINE | ID: mdl-10745540

ABSTRACT

We describe two patients with spontaneous coronary artery dissection (SCAD) while on immunosuppressive therapy following renal transplantation. The role of cyclosporine A as a potential etiologic factor in spontaneous coronary artery dissection is discussed. A review of the recent literature on spontaneous coronary artery dissection highlights the changing clinical presentation and management of these patients.


Subject(s)
Aortic Dissection/chemically induced , Coronary Aneurysm/chemically induced , Cyclosporine/adverse effects , Immunosuppressive Agents/adverse effects , Kidney Transplantation , Adolescent , Aortic Dissection/diagnostic imaging , Coronary Aneurysm/diagnostic imaging , Coronary Angiography , Female , Humans , Male , Middle Aged
14.
Curr Opin Lipidol ; 9(4): 301-7, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9739484

ABSTRACT

Although it is well established that dietary saturated fatty acid intake is an important risk factor for coronary heart disease, there remains substantial controversy regarding whether these dietary fatty acids should be replaced with either carbohydrates, monounsaturated fatty acids, polyunsaturated fatty acids or a combination of these. This review highlights recent studies evaluating the role of dietary fatty acids in atherosclerosis, with a particular emphasis on their roles in lipoprotein oxidation and other potential proatherogenic processes.


Subject(s)
Arteriosclerosis/epidemiology , Dietary Fats/metabolism , Fatty Acids/metabolism , Inflammation/metabolism , Lipoproteins, LDL/metabolism , Oxidation-Reduction , Risk Factors , Thrombosis/metabolism
15.
Cathet Cardiovasc Diagn ; 35(3): 262-5, 1995 Jul.
Article in English | MEDLINE | ID: mdl-7553837

ABSTRACT

We report a case of intravascular ultrasound (IVUS) imaging of a chronic total coronary artery occlusion angioplasty initially complicated by subintimal wire penetration. IVUS provided unique images of wire position and a "double-barrel" lumen that complemented angiographic data in initial diagnosis and in subsequent guidance of the procedure.


Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Coronary Disease/therapy , Coronary Vessels/injuries , Tunica Intima/injuries , Ultrasonography, Interventional , Adult , Angioplasty, Balloon, Coronary/methods , Constriction, Pathologic/therapy , Coronary Vessels/diagnostic imaging , Humans , Male
17.
Circ Res ; 66(2): 457-68, 1990 Feb.
Article in English | MEDLINE | ID: mdl-2153472

ABSTRACT

Adenosine (ADO) has an antiadrenergic action in the heart that causes an attenuation of contractile and metabolic responses elicited by beta-adrenergic stimulation. The effect of an increase in oxygen consumption elicited by either beta-adrenergic stimulation or an increase in contraction frequency on interstitial fluid and coronary effluent ADO levels was investigated in isolated perfused isovolumically contracting rat hearts. ADO in left ventricular surface transudates and coronary effluents was rendered fluorescent with chloroacetaldehyde, and the formed ethenoadenosine derivative was quantitated with high-performance liquid chromatography fluorescence detection. Heart preparation integrity was verified by determining the activities of lactate dehydrogenase and ADO deaminase in the transudates. Isoproterenol (10(-8) M) elicited a 45% increase in oxygen consumption and a 54% increase in developed left ventricular pressure in hearts paced at 240 beats/min. With isoproterenol the control transudate ADO concentration (304 pmol/ml) increased 493%, and the control effluent ADO concentration (48 pmol/ml) increased 259%. Increasing the contraction frequency from 180 to 300 beats/min in the presence of 10(-6) M propranolol increased oxygen consumption by 45% and decreased left ventricular pressure by 29%. With the increase in contraction frequency, the transudate ADO concentration did not increase significantly. However, the ADO concentration in the effluent was an average of 269% greater in hearts contracting at the higher frequency. Increasing the contraction frequency of hearts treated with both 10(-6) M propranolol and 10(-5) M atropine also had no significant effect on the level of transudate ADO. The effluent level of ADO increased only 78%. Levels of ADO in transudates were not significantly affected by mesothelial cell metabolism. These results suggest that the beta-adrenergic stimulation the interstitial level of ADO in the heart increases to levels that are sufficient to manifest its antiadrenergic effects. Furthermore, there is not always a correlation between the levels of ADO found in the interstitial and effluent fluid compartments.


Subject(s)
Adenosine/metabolism , Extracellular Space/metabolism , Myocardial Contraction , Myocardium/metabolism , Receptors, Adrenergic, beta/physiology , Adenosine Deaminase/metabolism , Animals , Atropine/pharmacology , Guinea Pigs , Isoproterenol/pharmacology , L-Lactate Dehydrogenase/metabolism , Male , Oxygen Consumption/drug effects , Pericardium/cytology , Pericardium/metabolism , Propranolol/pharmacology , Rats , Rats, Inbred Strains
18.
Arch Biochem Biophys ; 245(1): 282-6, 1986 Feb 15.
Article in English | MEDLINE | ID: mdl-3004359

ABSTRACT

We describe the synthesis of a mixture of D-manno- and D-gluco-2,5-anhydro-1-deoxy-1-phosphonohexitol 6-phosphate via a Horner-Emmons reaction of 2,3,5-tri-O-benzyl-beta-D-arabinofuranose followed by phosphorylation of the equivalent 6-position and subsequent deprotection. This mixture inhibits fructose-1,6-bisphosphatase; the concentration required for half-maximal effect in the presence of 25 microM AMP is approximately 6 microM. The mixture of analogs also stimulates 6-phosphofructo-1-kinase from rabbit liver; the concentration required to reach one-half Vmax was found to be ca. 25 microM at 0.25 mM fructose 6-phosphate and 50 microM AMP. These analogs have replaced the labile anomeric phosphate of fructose 2,6-bisphosphate with a stable methylenephosphonate, and could be of great interest due to their appropriate physiological effects and their chemical stability.


Subject(s)
Fructose-Bisphosphatase/antagonists & inhibitors , Phosphofructokinase-1/metabolism , Sugar Phosphates/pharmacology , Adenosine Monophosphate/metabolism , Animals , Enzyme Activation/drug effects , Fructosediphosphates/pharmacology , Liver/enzymology , Rabbits , Sugar Phosphates/chemical synthesis
SELECTION OF CITATIONS
SEARCH DETAIL
...